Deploying smart weapons in the fight against cancer.

Bellicum Pharmaceuticals, Inc. is developing novel therapies that can be precisely controlled after delivery, for enhanced efficacy and ultimate safety. Products for patients with metastatic castrate-resistant prostate cancer, and patients receiving a hematopoietic stem cell transplant, are in clinical development.

Learn More About Our Clinical Trials

Bellicum: Latin, (noun) Military signal to mobilize an attack; call to war

Now Hiring! Bellicum is now hiring. Please see our careers page for more information.

Dendritic Cell

DeCIDe™ Technology

Our drug activated DeCIDe vaccines are designed to kill targeted cells by inducing a potent, durable, fully activated antigen-specific T cell immune response.

Learn More About DeCIDe™
Transplant Cell

CaspaCIDe™ Technology

Transplanted cells containing a drug activated CaspaCIDe suicide gene can be rapidly eliminated in the event that they put the patient’s health at risk.

Learn More About CaspaCIDe™